<DOC>
	<DOCNO>NCT00374179</DOCNO>
	<brief_summary>RATIONALE : CT-322 may stop growth solid tumor non-Hodgkin 's lymphoma stopping blood flow cancer . PURPOSE : This phase I trial study side effect CT-322 treat patient advance solid tumor non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>CT-322 Treating Patients With Advanced Solid Tumors Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS Histologically proven advance solid malignancy NHL standard therapy exist standard therapy fail No know brain leptomeningeal disease No prior bone marrow transplant stem cell rescue No histologically confirm squamous nonsmall cell lung cancer ( NSCLC ) central chest tumor ( ) still place PATIENT CHARACTERISTICS Age : * 18 Performance status : * ECOG performance status ≤ 2 Life expectancy : * &gt; 3 month Hematopoietic : ANC ≥ 1500/mL Platelets ≥ 100,000/mL Hemoglobin ≥ 9.0 g/dL ; require transfusion &gt; 1 unit/month Hepatic : AST ALT ≤ 2.5 x ULN ; liver function abnormality due underlying malignancy , AST ALT may ≤ 5 x ULN Bilirubin ≤ 1.5 x ULN aPTT PT &lt; 1.5 x ULN Renal : Creatinine ≤ 1.5 x ULN ; patient serum creatinine &gt; 1 x ULN must also creatinine clearance ( base 24hour urine collection ) ≤ 60 mL/min No proteinuria &gt; 1+ dipstick analysis ; case &gt; 1+ dipstick proteinuria , 24hour urine collection protein must &lt; 500 mg/24 hour Urinary protein/creatinine ratio &lt; 1 No glomerulonephritis Cardiovascular : No coronary artery bypass graft , angioplasty , vascular stent , myocardial infarction , unstable angina , symptomatic congestive heart failure , severe uncontrolled hypertension , hemorrhagic thrombotic stroke CNS bleeding within precede 12 month LVEF normal echocardiogram MUGA within past 12 month prior exposure anthracyclines radiotherapy encompass heart Immunologic : * Not know human immunodeficiency virus ( HIV ) , active hepatitis virus C ( HVC ) , active hepatitis virus B ( HVB ) Other : Negative pregnancy test within 7 day prior enrollment Not pregnant breast feed Fertile patient must agree use effective contraception commit abstinence study period , surgically sterile No serious nonhealing wound , ulcer , bone fracture Have ability understand sign inform consent document Be willing able comply schedule visit , treatment plan , laboratory test , study procedure PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics At least 4 week since prior biological immunotherapy recover Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy recover At least 6 week mitomycin C nitrosoureas prior study entry recover Radiotherapy : * At least 4 week since prior radiotherapy visceral organ recover Surgery : At least 4 week since prior major laparoscopic surgery recover At least 1 week since prior minor surgery Other : No concurrent anticancer therapy Not concurrently enrol another therapeutic clinical trial involve ongoing therapy No concurrent full dose , therapeutic anticoagulation warfarin related oral anticoagulant unfractionated low molecular weight heparin ; low dose warfarin catheter prophylaxis acetylsalicylic acid ≤ 325 mg/day acceptable</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
</DOC>